Syndax Pharmaceuticals
Biotechnology
See how your profile stacks up against this role.
We compared the job requirements to your profile to show where you're strong and where you fall short.
Syndax Pharmaceuticals is looking for a Senior Director, Clinical Pharmacology
At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies.
The Role:
Syndax is seeking a strategic and experienced Clinical Pharmacology leader to drive clinical pharmacology and model-informed drug development (MIDD) strategies across our development portfolio. Reporting to the Head of Clinical Pharmacology, this individual will provide scientific and strategic leadership for small molecule development programs, leading clinical pharmacology studies and applying quantitative approaches to inform dose optimization and key development decisions from early development through global regulatory submissions. This role offers a unique opportunity to influence development strategy, advance innovative therapies, and help shape the future growth of the Clinical Pharmacology function at Syndax.
Key Responsibilities:
Desired Experience/Education and Personal Attributes:
Location: Syndax’s corporate office is in New York, NY.
Syndax offers a total compensation and rewards package that is among the most competitive in the industry. Base pay is just one element of our package and is determined within a range based on several factors including market data, experience, qualifications, demonstrated skills, relevant education or training, travel requirements and internal equity. Our overall package also includes an equity offering, annual target bonuses, and an outstanding benefits program. The anticipated annualized salary range for this role is $285,000 - $305,000.
About Syndax:
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Pharmaceuticals is an equal opportunity employer and will not discriminate against any employee or applicant on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any classification protected by federal, state, or local law.
#LI-Remote
After you apply, unlock the direct contact details of the people who actually make the call. A quick follow-up makes you 5x more likely to land an interview.
Marcus Rivera
Chief Revenue Officer

TSMG Holding

It's Caliber

AHEAD

Snowflake

Outsourcey

Syndax Pharmaceuticals

Syndax Pharmaceuticals

Syndax Pharmaceuticals